阿兹屈南
亚胺培南
微生物学
肺炎克雷伯菌
抗菌剂
生物
大肠杆菌
抗生素
抗生素耐药性
生物化学
基因
作者
Mark Biagi,Michelle Lee,Ting Wu,A Shajee,SR Patel,Deshpande LM,Mendes RE,Eric Wenzler
标识
DOI:10.1016/j.diagmicrobio.2022.115674
摘要
The objective of this study was to evaluate the in vitro activity of aztreonam plus imipenem-relebactam against clinical and isogenic strains of Escherichia coli and Klebsiella pneumoniae co-harboring NDM and >1 serine β-lactamase.Thirteen isolates were included: 4 clinical E. coli, 4 clinical K. pneumoniae, and 5 isogenic E. coli. Drugs were tested in time-kill analyses alone, in dual β-lactam combinations, and in triple drug combinations against all strains.All isolates were resistant to imipenem and imipenem-relebactam, and 85% were aztreonam-resistant. Neither imipenem nor imipenem-relebactam was bactericidal alone while aztreonam was bactericidal against 54% of isolates. The combination of aztreonam+imipenem was bactericidal and synergistic against 7/13 and 10/13 isolates. The addition of relebactam to this combination resulted in synergy against all 11 aztreonam-resistant clinical isolates.Aztreonam plus imipenem-relebactam may be a viable treatment option for aztreonam-non-susceptible NDM and serine β-lactamase-producing E. coli and K. pneumoniae.
科研通智能强力驱动
Strongly Powered by AbleSci AI